EDA Welcomes Celmatix Clinical Laboratories to CCIT
Celmatix Clinical Laboratories Lab Supervisor LisaMarie Ross prepares DNA samples for testing.
North Brunswick, N.J. (January 31, 2017) – The New Jersey Economic Development Authority (EDA) today announced that Celmatix Clinical Laboratories, a subsidiary of digital health technology industry leader Celmatix, has established its new laboratory at the EDA’s Commercialization Center for Innovative Technologies (CCIT) in North Brunswick.
“New Jersey is widely recognized as a leader in innovation,” EDA Chief Executive Officer (CEO) Melissa Orsen said. “Combined with CCIT’s array of resources available to emerging life sciences companies, it’s easy to see why Celmatix Founder and CEO Dr. Piraye Yurttas Beim chose to locate Celmatix Clinical Laboratories at our facility.”
Celmatix was founded to create products that bring greater clarity to the treatment of infertility and pave the way for women to proactively manage their fertility throughout their reproductive life. Through its products, Celmatix strives to use big data analytics and genomics to help clinics optimize patient outcomes and enhance the patient experience.
Under Beim’s direction, Celmatix recently announced Fertilome®, the world’s first multigene panel test that reveals how a woman’s DNA may affect her reproductive health. The test is available through physicians and gives women unique genetic insights, allowing them to make more informed, proactive reproductive health decisions. Fertilome® is the result of a multi-year systematic literature review and statistical validation analysis to identify genetic variants that are significantly associated with the most common female reproductive conditions.
“Women struggling with infertility often feel a loss of control over something that is so personal to them, their reproductive health,” Beim said. “Celmatix is committed to empowering women with more personalized information and insights and the work that we plan to do at CCIT will further this mission.”
Strategically located in the heart of the State’s research corridor between Rutgers and Princeton universities, CCIT offers 27 wet labs, the most of any incubator in New Jersey. Currently home to nearly two-dozen businesses, the 46,000-square-foot incubator includes both small and large labs, as well as offices. CCIT also offers discounted first-year rent for university spinouts. Additionally, CCIT provides tenant companies like Celmatix Clinical Laboratories with educational programs and a host of supporting resources, including help to identify funding sources and access to small business development resources, networking opportunities and administrative support. The incubator routinely hosts events such as New Jersey Founders & Funders, which introduces startup companies to angel and venture investors, and Lunch & Learn presentations that bring in industry experts to discuss topics relevant to emerging companies.
CCIT is located within the Technology Centre of New Jersey, a 75-acre research park that houses such companies as Chromocell and Orthobond (both of which are CCIT graduates), Allergan, and Merial. Companies interested in touring CCIT should visit www.njeda.gov/CCIT or contact Lenzie Harcum at lharcum@njeda.com.
For more information about resources available to support New Jersey’s technology industry, visit https://www.njeda.gov/tls and follow @NJEDATech on Twitter and LinkedIn.
###
